太龙药业: 太龙药业关于取消监事会并修订《公司章程》及部分治理制度的公告

Core Viewpoint - The company, Henan Tailong Pharmaceutical Co., Ltd., has announced the cancellation of its supervisory board and the revision of its articles of association and governance systems to enhance corporate governance and compliance with updated regulations [1][2]. Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board, and its functions will be transferred to the audit committee of the board of directors [1]. - This decision is in line with the latest amendments to the Company Law of the People's Republic of China and other relevant regulations [1][2]. Group 2: Revision of Articles of Association - The articles of association have been revised to reflect the cancellation of the supervisory board, with relevant descriptions replaced by references to the audit committee [2]. - Specific changes include the rephrasing of clauses to maintain the rights and interests of the company, shareholders, and creditors, while ensuring compliance with the updated legal framework [2]. Group 3: Governance Structure - The company aims to improve its governance structure and operational standards by eliminating the supervisory board, which is expected to streamline decision-making processes [1][2]. - The audit committee will now assume the responsibilities previously held by the supervisory board, enhancing oversight and accountability within the company's governance framework [1].